Psychopathologies may occur in heart failure (HF) and can be associated with adverse outcomes. Amongst neuropeptide S receptor gene functional sequence variants, the T-allele [asparagine(107)isoleucine, NPSR1 rs324981] has been identified as a risk factor for increased anxiety/overinterpretation of bodily symptoms. We investigated all-cause death and re-hospitalization (composite primary endpoint, CPEP) and healthcare utilization in patients hospitalized for decompensated systolic HF with the TT vs. the AT/AA genotype. 
Introduction
About 15 million Europeans and 5.7 million US Americans have heart failure (HF), rates of HF-related hospital admissions and death are high, and estimated annual costs attributable to HF amount to ∼2% of total national healthcare expenditures in both Europe and the USA.
1 -3 Psychiatric syndromes such as depression and anxiety are common in HF, 4, 5 and their adverse impact on clinical outcomes and costs is increasingly recognized. 6 -8 However, knowledge about the neurobiological mechanisms mediating these prognostic effects and possible treatment options remains scarce.
Neuropeptide S (NPS) is a recently described molecule that acts via the G-protein-coupled NPS receptor (NPSR1) 9 and is a key regulator of anxiety and activity in rodents.
10 NPSR1 is widely distributed in the brain and is mainly co-expressed with NPS; highest expression levels are found in the brainstem, mid-and forebrain, cortex, hippocampus, and hypothalamus. 10 Within the gene encoding NPSR1, a common polymorphism (rs324981 A/T) causes an amino acid transition at position 107 (Asn107Ile). The T-allele has a frequency of 47% (1000 Genomes project) and leads to isoleucine substitution with an ∼10-fold increase in NPSR1 expression and significantly increased NPS-induced signal responses.
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We previously demonstrated an association of the NPSR1 gene rs324981 A/T [Asn(107)Ile] polymorphism with panic disorder and agoraphobia, and an association with higher Anxiety Sensitivity Index scores in response to bodily symptoms.
12 T-allele carriers exhibited activation of the dorsal anterior cingulate cortex during fear learning, indicating a cognitive overinterpretation of fear reactions. 13 More recently, increased activation of the right prefrontal cortex was shown in TT genotype carriers during an Attentional Network Task, suggesting a role for NPSR1 both in integration of the perception of bodily symptoms (bottom-up alerting) and in the subsequent cognitive response (executive neural control).
14 Correspondingly, significant interactions between genotype and environment have been observed, implicating an increased anxiety sensitivity in healthy persons with the homozygous TT genotype. 15, 16 Until now, the role of the NPS system has not been investigated in HF patients, who experience bodily symptoms such as dyspnoea, fatigue, and physical incapacity as part of their somatic illness. To investigate whether the NPSR1 rs324981 A/T [Asn(107)Ile] polymorphism modulates outcomes in this severe somatic disease, we studied the characteristics and clinical course of patients discharged from hospital after acute cardiac decompensation according to NPSR1 genotype using data and biomaterials from the Interdisciplinary Network Heart Failure (INH) programme. 17 In consideration of functionality, and previous studies on anxiety-related phenotypes that suggested a recessive effect of the T-allele,
12 -16 we primarily tested the hypothesis that clinical outcomes and healthcare utilization might differ between patients with the AT or AA genotype and homozygous carriers of the gain-of-function T-allele (TT genotype) as a possible consequence of the genetically determined exaggerated perception of somatic symptoms and over-reaching anxiety.
. 
Methods

Setting and study design
The INH physicians developed a collaborative nurse-co-ordinated disease management programme, HeartNetCare-HF™ (HNC), and evaluated its effects on the risk of all-cause mortality and re-hospitalization (primary composite endpoint) compared with usual care (UC) using a randomized controlled design. 17 At nine study sites, patients hospitalized for acute decompensation of systolic HF were recruited before discharge. The study protocol conformed with the Declaration of Helsinki and was approved by all ethics committees responsible. All participants in this post-hoc analysis fulfilled INH inclusion and exclusion criteria, 17 and provided written informed consent including permission for genetic testing. Follow-up in the INH study, 17 and this analysis of trial data, was 180 days (100% complete).
Study intervention
Patients in the HNC arm were provided with teaching materials and training in self-supervision by specialist nurses while still hospitalized. Also during hospitalization, patients and relatives practised self-assessment of vital parameters and signs of worsening HF. Within 7 days after discharge, nurses initiated telephone-based monitoring using a 19-item questionnaire. 17 Weekly telephone contacts during the first month were used to implement HNC, which also involved tolerance-guided up-titration of HF pharmacotherapy and patient counselling and empowerment. 17 Contact frequencies were then adapted according to patients' NYHA class at discharge (fortnightly or weekly in NYHA III-IV, monthly in NYHA I-II) and individual needs.
Data collection and psychometric evaluation
Baseline assessments included a physical examination, standard laboratory testing, collection of biomaterials, ECG, quantitative echocardiography, and psychometric evaluation. All participants received patient passes, which served to document hospital admissions and physician visits between discharge and the 6-month follow-up. Nurses used structured paper-based forms to document items discussed and actions taken during HNC application in patients receiving the intervention.
The self-assessment 9-item Patient Health Questionnaire (PHQ-9) 18 and the Kansas City Cardiomyopathy Questionnaire (KCCQ) 19 were used to evaluate depressive symptoms and health-related quality of life, respectively.
Biomarker assessment
Biomaterials sampled at baseline were stored at −80 ∘ C. After completion of the 18-month follow-up, NT-proBNP and cortisol were measured using a solid-phase two-site chemiluminescent immunometric assay on a Siemens IMMULITE 2000 system (Siemens Healthcare Diagnostics GmbH, Eschborn, Germany). A randomly selected subgroup (n = 194) also provided saliva in a special collection device (Salivette ® , Sarstedt, Nümbrecht Rommelsdorf, Germany). Sampling times were 08:00 and 21:00 h to capture circadian changes. On the next day, the devices were centrifuged at 3000 rpm for 5 min, and the supernatant was stored. Salivary cortisol was determined with a commercial immunoassay based on luminescence detection (IBL, Hamburg, Germany).
Genotyping
DNA was isolated from venous whole blood samples. NPSR1 rs324981 was genotyped using a standard PCR procedure (45 s at 95 ∘ C, 45 s at 58 ∘ C, 45 s at 72 ∘ C for 35 cycles) using oligonucleotide primers F: 5'-TGCTTTGCATTTCCTCAGTG-3' and R: 5'-TTGTCTC ATCACATTTGGAAGG-3' flanking the polymorphic region. For genotype determination, the PCR product (294 bp) was digested with AseI [NEB, Frankfurt (Main), Germany] at 37 ∘ C for 3 h. Subsequently, fragments were visualized on a 3% agarose gel. The call rate was >99%; duplicate genotyping was carried out randomly and yielded 100% reproducibility. Hardy-Weinberg equilibrium, assessed with the online program DeFinetti (Wienker and Strom, accessed November 2015), was fulfilled for NPSR1 genotype distribution in the present sample (AA, n = 278; AT, n = 448; TT, n = 198; P = 0.51) and similar to the distribution in previous German samples. 12, 15 Genotyping was performed by personnel unaware of patients' randomization status.
Endpoints
Primary study outcomes were the time to either all-cause death or re-hospitalization (composite primary endpoint) and both components separately. General practitioners' and specialists' records, hospital discharge letters, reports from patients and relatives, and death certificates were used as source documents to adjudicate hospital re-admissions and determine the date of death in deceased patients. Secondary endpoints included the number and type of outpatient physician contacts, which were extracted from the patient passes and confirmed by comparison with general practitioners' records. Information on items discussed and actions taken by the nurses during and after telephone contacts was extracted from the nurses' documentation sheets by a single investigator (D.M.), who was unaware of patients' genotype. Patients' vital status was ascertained after 180 days either during a personal visit to the INH outpatient clinics or by telephone follow-up.
Data analysis and statistics
Homozygous T-allele carriers were compared with pooled data from patients with the AT and AA genotypes. Data are given as mean ( ± SD), median (quartiles), or n (percentage), as appropriate. For comparisons of demographic and clinical variables between groups, Kruskal-Wallis, Mann-Whitney U-test, or 2 test were employed, as appropriate. For analysis of primary endpoint events, Kaplan-Meier estimates were used to assess the incidence of all-cause death and re-hospitalization considering AA or AT vs. TT genotypes only and, in a further analysis, also the mode of care. A similar exploratory analysis considered the three genotypes (AA, AT, and TT) separately.
Univariable and multivariable Cox proportional hazards regression models were used to assess further inter-relationships between genotypes and mode of care. The multivariable regression model was built with the following covariates: age, sex, NYHA class, haemoglobin, glomerular filtration rate, LVEF (two-dimensional echocardiography), and PHQ-9 sum-score. 18, 20 Hazard ratios (HRs) are reported with 95% confidence intervals (CIs). Because there was evidence of violation of the proportional hazards assumption, the regression was performed time-stratified from 0-35 and >35 days. 21 The separation point was determined by visual analysis of the curves and refined by analysis of survival tables. There was no adjustment for multiple endpoints. For analysis of secondary endpoints, type and frequencies of care modules applied in the HNC arm in patients with the AT or AA vs. TT genotypes and the number of outpatient physician contacts in UC-and HNC-treated subgroups were compared using Mann-Whitney U-test.
Reported P-values are two-sided. P-values <0.05 were considered statistically significant. Tables were created using R. 22 All other analyses were performed using SPSS (SPSS 21.0; SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Patient demographic and clinical characteristics at baseline in the overall population (n = 924), and in subgroups by genotype and/or treatment group are shown in Tables 1 and 2 . Patient subgroups were largely comparable, apart from a significantly lower proportion of patients with a HF duration of >1 year in patients with the TT vs. the AT/AA genotype ( Table 1) and a significantly higher level of cortisol in saliva in TT genotype patients in the UC group ( Table 2) . The proportion of patients with the TT genotype was 20.4%, similar to that in a population-based sample.
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Clinical outcomes
After 180 days, the composite primary endpoint was reached by 181 HNC (39%) and 195 UC (42%) patients (HR for UC 1.08, 95% CI 0.88-1.32, P = 0.474). All-cause death had occurred in 36 HNC (8%) and 55 UC (12%) patients (HR 1.54, 95% CI 1.01-2.35, P = 0.044) and re-hospitalization in 164 HNC (36%) and 177 UC (38%) patients (HR 1.08, 95% CI 0.87-1.33, P = 0.485).
The upper panels of Figure 1 show Kaplan-Meier estimates for the primary endpoint and its components according to genotype. Patients with the TT genotype experienced a significantly higher rate of composite endpoint events than those with the AT or AA genotype [92 (47%) vs. 284 (39%) events, HR 1.27, 95% CI 1.01-1.61, P = 0.044, Figure 1A] . The risk of all-cause mortality was similar between genotypes [21 (11%) vs. 70 (10%) events, HR 1.11, 95% CI 0.68-1.81, P = 0.664, Figure 1B ], but patients with the TT vs. AT or AA genotype were re-hospitalized significantly more often [85 (43%) vs. 256 (35%) events, HR 1.31, 95% CI 1.02-1.67, P = 0.033, Figure 1C ]. Multivariable analysis did not materially change these results ( Table 3) .
The course of events according to both treatment allocation and genotype is shown in the lower panels of Figure 1 . Until day 35 after randomization, there were no significant differences between the four patient subgroups. Between day 35 and day 180, however, homozygous TT carriers undergoing HNC showed the highest incidence of the composite endpoint, whereas AT/AA carriers on HNC had the lowest [48 (51%) vs. 133 (36%), HR 2.14, 95% CI 1.44-3.19, genotype × treatment interaction P = 0.007, Figure 1D dashed curves]. This result was exclusively driven by higher re-hospitalization rates in the TT group, because 45 (47%) of TT genotype patients but only 119 (33%) of the AT/AA patients were re-admitted to hospital at least once during the observation period (HR 2.29, 95% CI 1.52-3.44, genotype × treatment interaction P = 0.007, Figure 1F , dashed curves). In contrast, mortality risk was not statistically different in TT and AT/AA carriers undergoing P-values refer to any difference between subgroups. Anaemia, haemoglobin <12 mg/dL (females) or <13 mg/dL (males); BMI, body mass index; cortisol, from serum (n = 863) or saliva (n = 194); depression, Patient Health Questionnaire score (PHQ) ≤11 vs. >11; diabetes mellitus, from patient history; eGFR, estimated glomerular filtration rate; HF, heart failure; heart rate, from ECG; hypertension, from patient history; KCCQ, Kansas City Cardiomyopathy Questionnaire (n = 792); LVEF, from two-dimensional echocardiography (n = 904); MR, mineralocorticoid receptor; NT-proBNP (n = 866); PHQ (n = 798); renal dysfunction, eGFR <60 mL/min/1.73 m 2 (Modification of Diet in Renal Disease formula).
HNC [6 (6%) vs. 30 (8%), respectively, genotype × treatment interaction P = 0.363, Figure 1E, Figure 1B) , and multivariable analysis did not materially change the results ( Table 3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P-values refer to any difference between subgroups. Anaemia, haemoglobin <12 mg/dL (females) or <13 mg/dL (males); BMI, body mass index; cortisol, from serum (n = 863) or saliva (n = 194); depression, Patient Health Questionnaire (PHQ) score ≤11 vs. >11; diabetes mellitus, from patient history; eGFR, estimated glomerular filtration rate; HF, heart failure; heart rate, from ECG; hypertension, from patient history; KCCQ, Kansas City Cardiomyopathy Questionnaire (n = 792); LVEF, from two-dimensional echocardiography (n = 904); MR, mineralocorticoid receptor; NT-proBNP (n = 866); PHQ (n = 798); renal dysfunction, eGFR <60 mL/min/1.73 m 2 (Modification of Diet in Renal Disease formula). 
Intervention flow by genotype
Outpatient physician contacts
In the UC group, the total number of contacts with general practitioners were 11.7 ± 11.1 vs. 13.4 ± 11.5 in patients with the TT and AT/AA genotypes, respectively (including home and office visits, P = 0.103). Corresponding numbers for cardiologist visits were 0.6 ± 1.3 vs. 0.8 ± 2.6 (P = 0.760) and for other specialist visits 3.0 ± 12.0 vs. 2.5 ± 10.7 (P = 0.078), respectively. (13.7 ± 10.2 and 13.0 ± 10.1, P = 0.663). However, TT genotype patients paid significantly more visits to cardiologists (0.9 ± 1.0 vs. 0.7 ± 2.2, P = 0.009) and other specialists (2.9 ± 10.4 vs. 1.4 ± 6.6, P = 0.005) than those with the AA or AT genotypes. These differences persisted when physician contacts were analysed by months alive and out of hospital ( Table 5) .
Discussion
This post-hoc analysis from the INH programme showed that within 180 days after discharge from hospital after acute decompensation of systolic HF, homozygous carriers of the gain-of-function T-allele experienced significantly more composite primary endpoint events than those with the AT or AA genotype, = 365) in HNC  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . We did not find any differences between patients with the TT genotype and those with the AT/AA genotype regarding demographic or HF characteristics, including NYHA class, NT-proBNP levels, a variety of clinical features, and co-morbidity profile. Thus, unequal post-discharge healthcare utilization cannot be explained by differences in HF severity. Moreover, health-related quality of life as assessed by the KCCQ 19 and PHQ-9 sum-scores as a measure of depressive symptoms, 18 which both correlate with clinical outcomes, 23, 24 were impaired to a similar degree, and the proportion of patients with suspected major depression based on a PHQ-9 sum-score >11 18 was comparable in both genotype subgroups. This indicates that, surprisingly, there was no interaction of the T 'risk' allele with these psychogenic risk factors. Exploratory analysis of the effects of the NPSR1 genotype on serum and circadian salivary cortisol revealed no clinically relevant differences between patients with the TT or AT/AA genotype either. We performed this analysis because previous studies had suggested an association of NPSR1 with activation of the hypothalamus-pituitary-adrenal axis and the cortisol response to stress. 25 The fact that these peripheral endocrine markers obviously lacked sensitivity to detect differential effects of the NPSR1 variant rs324981 on stress regulation and coping ability in our patients might, at least partly, be related to modulation of cortisol levels by HF severity per se 26 and also to treatment, because many patients were taking a mineralocorticoid receptor antagonist. 27 Consistent with previous psychiatric and psychological studies, 15, 16 an exploratory analysis of clinical outcomes in the three genotype subgroups separately (AA, AT, and TT) did not suggest an intermediate phenotype (i.e. a dose-gene effect).
The HNC intervention involved repeat telephone contacts with specialist HF nurses, tolerance-guided up-titration of HF pharmacotherapy, patient counselling and empowerment including procurement of self-care and self-supervision skills, regular monitoring of HF signs and symptoms, and opportunities for patients to discuss their individual problems. 17 Contrary to our expectations, there were no apparent differences in HNC utilization patterns between the genotype subgroups. Therefore, trigger mechanisms for the increased healthcare utilization in TT genotype carriers remain speculative. One possibility might be that during telephone contacts the TT genotype carriers exaggerated self-assessed somatic symptoms, which could have led nurses more frequently to recommend assessment of problems they perceived as potentially dangerous. Approaching a cardiologist or visiting the emergency room following such nurse recommendations would have increased both the number of specialist visits and the likelihood of re-hospitalization. Because patients managed with UC had fewer interactions with healthcare professionals, opportunities to trigger this sequence of events were less frequent.
Numerically, TT genotype carriers had the lowest all-cause mortality risk when being managed with HNC, and the highest when undergoing UC, while no such differences were observed in patients with the AT or AA genotype. There was, however, . . We previously speculated that 'adequate early readmissions might have prevented fatalities, thus contributing to lower mortality rates in HNC patients'. 17 Our present analysis suggests that excess hospitalization could at least partly have been the consequence of a genotype × treatment interaction in rs324981 genotype carriers.
A major strength of our analysis is that the single nucleotide polymorphism studied was shown to have functional and behavioural effects in previous psychiatric and psychological studies, and the extrapolation that corresponding mechanisms might have been active in our HF population mediating the increased risk of hospitalization seems reasonable. However, we cannot definitely exclude the possibility that the increased risk of hospitalization in the TT genotype group undergoing HNC was due to confounding factors not assessed as part of the INH study. To account at least partly for this inherent limitation of our post-hoc analysis, an adjusted model was used. Furthermore, there were no obvious differences between study patients across genotype and treatment groups. Finally, the total number of events reported was relatively small, which limits the strength of our findings. In addition to validation in larger prospective studies, specific anxiety profiling (not available from the INH study) is needed to better define the functional and behavioural effects of NPSR1 on HF phenotypes and provide further insight into possible underlying pathophysiological mechanisms.
In summary, our results suggest a modulation of clinical outcomes and healthcare utilization by genetic variation in NPSR1 in interaction with HNC disease management. In light of the continuously increasing prevalence of HF worldwide, the poor prognosis of this disease, and rapidly escalating costs for HF care, 1 -3 current guidelines urgently call for 'tailored' comprehensive therapy in high-risk patients after cardiac decompensation. 1 We have previously shown that genetic variation modulates the efficacy of psychotherapy in mental disorders. 28 Indications from this 'proof-of-concept' study that the rs324981 genotype may be a determinant of healthcare utilization in HF patients demonstrate for the first time that psychiatric phenotypes could also play a role in somatic diseases. Given the moderate costs of genotyping NPSR1, routine assessment would be affordable.
Prospective research is warranted to ensure that knowledge of the TT genotype does not result in bias against adequate reactions to reported worsening of HF and other medically significant events in patients with this genotype. Additional studies are also needed to clarify whether assessment of psychogenic determinants of treatment efficacy and healthcare utilization (e.g. NPSR1 genotyping) might contribute to achieving the concept of 'personalized' medicine in HF.
